Oncotarget · 2016 · 160 citations · 31 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer BiomarkersCancer ImmunotherapyImmune Checkpoint InhibitorsImmuno-oncology BiomarkersImmunotherapy For Skin CancerMelanoma PharmacotherapyC-reactive Protein TestingImmune Checkpoint Inhibitor BiomarkersImmune MarkersMelanoma BiomarkersMelanoma ImmunotherapyPrognostic Factors AnalysisProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 Inhibitors
// Yoshio Nakamura 1, 3 , Shigehisa Kitano 2, * , Akira Takahashi 1 , Arata Tsutsumida 1 , Kenjiro Namikawa 1 , Keiji Tanese 3 , Takayuki Abe 4 , Takeru Funakoshi 3 , Noboru Yamamoto 2 , Masayuki Amagai 3 , Naoya Yamazaki 1, * 1 Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan 2 Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan 3 Department of Dermatology, Keio University School of Medicine, Tokyo, Japan 4 Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical Translational Research Center, Keio University School of Medicine, Tokyo, Japan * These authors have contributed equally to this work Correspondence to: Shigehisa Kitano, email: skitano@ncc.go.jp Keywords: nivolumab, metastatic melanoma, absolute lymphocyte count, absolute neutrophil count, early markers for outcome Received: June 07, 2016     Accepted: September 28, 2016     Published: October 15, 2016 ABSTRACT Background: An anti-programmed cell death protein 1 monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Tumor cell-derived or immune cell-derived markers and clinical predictors such as serum lactate dehydrogenase (LDH) and cutaneous adverse events, have already been described as prognostic factors for advanced melanoma treated with nivolumab. We sought to identify further clinical predictors that can be determined in routine clinical practice. Methods: We retrospectively analyzed clinical findings of 98 consecutive patients with unresectable stage III or IV melanoma treated with nivolumab, at the National Cancer Center Hospital or at Keio University Hospital, in Tokyo, Japan, between July 2014 and July 2016. These patients had been administered nivolumab at a dose of 2mg/kg every 3 weeks. Results: As for pretreatment prognostic factors, ECOG performance status (PS) ≥1, maximum tumor diameters of ≥30mm, elevated LDH and elevated C-reactive protein were significantly associated with poor overall survival (OS) (hazard ratio [HR] 0.29 [ P <0.001], HR 0.40 [ p =0.003], HR 0.29 [ P <0.001], HR 0.42 [ P =0.004], respectively) on univariate analysis. Among these factors, PS and LDH were identified as independent variables by multivariate analysis. As for early markers examined during therapy, patients with absolute lymphocyte count (ALC) ≥ 1000/μl (Week3: HR 0.40 [ P =0.004], Week6: HR 0.33 [ P =0.001]) and absolute neutrophil count (ANC) <4000/μl (Week3: HR 0.46 [ P =0.014], Week6: HR 0.51 [ P =0.046]) had significantly better OS. Conclusion: ALC≥1000/μl and ANC<4000/μl during treatment appear to be early markers associated with OS. Nivolumab might have minimal efficacy in patients with a massive tumor burden.
31
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14